METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation

Rui-Feng Yang Qin-Tao Ge Feng-Yao Wu Man-Mei Long Bingyu Li Zhe Hong Wen-Hao Xu Miaomiao Guo Tao Feng Xi Tian Wei Zhang Kun Chang Fangning Wan Zhi Shang Zhong-Yuan Wang Ming Zhan Bin Xu Ding-Wei Ye

Jul 2026 · Oncogene · Vol 45, pp. 3497 - 3510 · 0 citations · 36 references

Medicine

TL;DR

The findings uncover an unappreciated mechanism linking rRNA modification to mitochondrial homeostasis through selective translational control, providing new insights into metabolic regulation and revealing actionable vulnerabilities in advanced prostate cancer.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Sep 2026

Targeting the METTL5–MGST1 axis for cancer therapy: molecular mechanisms and therapeutic implications

This review comprehensively examines the structural biology, expression patterns, molecular mechanisms, and cancer-type-specific functions of both METTL5 and MGST1, with particular emphasis on their functional interdependence.

Abinash Nayak, S. Nishank · Molecular Biology Reports · 0 citations

Open access Sep 2026

Nuclear IDH3A Drives Transcriptional Programs in Melanoma via the YBX1–JUN/FOS Axis

It is demonstrated that IDH3A is significantly overexpressed in melanoma, primarily due to DNA copy number amplification, and a noncanonical role of IDH3A is uncovered as a nuclear regulator of transcription via YBX1, offering novel insight into metabolic enzyme reprogramming in melanoma.

Juan Ran, Yan-Chun Fang, Sheng-Ming Ruan et al. · Advancement of science · 0 citations

Open access Aug 2026

Epigenetically driven GAS2L3 enforces non-canonical cell cycle progression to promote osimertinib resistance in lung adenocarcinoma

These results uncover a metabolism-epigenetics–cell cycle interface that may represent a therapeutic vulnerability in EGFR-mutant LUAD and identify a glycolysis–H4K8la–GAS2L3 axis that drives noncanonical cell-cycle reprogramming independently of classical Cyclin–CDK activation, thereby promoting acquired osimertinib r...

Shu-Man Zhen, Xiaohui Bai, Shu-Tang Liu et al. · Cell Death Discovery · 0 citations

Aug 2026

NAT10 promotes prostate cancer progression by acetylating mRNA of MARK2 and activating mTOR/HIF-1α/C-Myc pathway to enhance glycolytic reprogramming.

Mechanistic investigations demonstrated that NAT10 elevates MARK2 expression, activating the mTOR/HIF-1α/C-Myc signaling cascade, thereby promoting aerobic glycolysis in PCa cells, suggesting that targeting ac4C mRNA modifications may provide a novel therapeutic strategy for managing prostate cancer.

Yi-Ming Zhang, Jian Wang, Gan-Ping Wang et al. · Cancer Gene Therapy · 0 citations

Sep 2026

METTL15-mediated m4C modification regulates glucose metabolic reprogramming via c-Myc-dependent mechanisms and promotes hepatocellular carcinoma progression.

Although aerobic glycolysis is a hallmark of hepatocellular carcinoma (HCC) progression, the underlying epitranscriptomic mechanisms remain poorly understood. Here, we identify METTL15, an N4-methylcytidine (m4C) RNA methyltransferase, as a novel oncogenic driver of this metabolic reprogramming. METTL15 is significantl...

Longhui Xie, Ken Ning, Yu-Hu Wang et al. · International Journal of Bio... · 0 citations

Open access Sep 2026

Targeting FEN1 disrupts EIF4A3-mediated MUC1-C autoregulation: a novel strategy to suppress lung adenocarcinoma progression

The FEN1/EIF4A3/MUC1-C axis is established as a novel mechanism driving LUAD progression by concurrently regulating intrinsic malignancy and extrinsic immune evasion, presenting FEN1 targeting as a promising dual-hit therapeutic strategy.

Min Wu, Ben-Meng Wu, Xue-Bing Yan et al. · Cell Death and Disease · 0 citations